Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of April 2026. The filing details a share repurchase executed on April 2, 2026, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and does not provide revenue, profit, cash flow, margin, or debt metrics.
- Shares Purchased (April 2, 2026): 335,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,093.00p; highest price paid was 2,161.00p.
- Volume-Weighted Average Price (VWAP): 2,121.37p.
- Cumulative Programme Activity: Since February 17, 2026, the Company has purchased 16,901,521 ordinary shares.
- Treasury Holdings: Following this purchase, the Company holds 256,792,615 ordinary shares in treasury.
- Shares in Issue: 4,059,387,166 ordinary shares (excluding Treasury shares).
- Voting Rights: Total voting rights are 4,059,387,166. Treasury shares represent 6.33% of voting rights.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the Company. There are no material changes to the Company's financial position, operations, or capital structure outside of the specific share buyback activity detailed above.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, operational outlook, or management commentary regarding future performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 17, 2026 (16,901,521 shares).
- Confirm the updated treasury share count (256,792,615 shares) and the percentage of voting rights held in treasury (6.33%).
- Review the specific trading venues (BATE, CHIX, XLON) and individual transaction prices to ensure compliance with the non-discretionary agreement.
- Check the Company's Form 20-F for 2025 for detailed risk factors referenced in the cautionary statement.